Practical management of patients with myelofibrosis receiving ruxolitinib

Claire Harrison, Ruben Mesa, David Ross, Adam Mead, Clodagh Keohane, Jason Gotlib, Srdan Verstovsek

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Myelofibrosis (MF) is characterized by bone marrow fibrosis, progressive anemia and extramedullary hematopoiesis, primarily manifested as splenomegaly. Patients also experience debilitating constitutional symptoms, including sequelae of splenomegaly, night sweats and fatigue. Ruxolitinib (INC424, INCB18424, Jakafi, Jakavi), a JAK1 and JAK2 inhibitor, was approved in November 2011 by the US FDA for the treatment of intermediate-or high-risk MF, and more recently in Europe and Canada for the treatment of MF-related splenomegaly or symptoms. These approvals were based on data from two randomized Phase III studies: COMFORT-I randomized against placebo, and COMFORT-II randomized against best available therapy. In these studies, ruxolitinib rapidly improved multiple disease manifestations of MF, reducing splenomegaly and improving quality of life of patients and potentially prolonging survival. However, as with other chemotherapies, ruxolitinib therapy is associated with some adverse events, such as anemia and thrombocytopenia. The aims of this article are to provide a brief overview of ruxolitinib therapy, to discuss some common adverse events associated with ruxolitinib therapy and to provide clinical management recommendations to maximize patients' benefit from ruxolitinib.

Original languageEnglish (US)
Pages (from-to)511-523
Number of pages13
JournalExpert Review of Hematology
Volume6
Issue number5
DOIs
StatePublished - 2013

Fingerprint

Primary Myelofibrosis
Splenomegaly
Anemia
Therapeutics
Extramedullary Hematopoiesis
Sweat
Thrombocytopenia
Canada
Fatigue
INCB018424
Placebos
Quality of Life
Drug Therapy
Survival

Keywords

  • JAK inhibitor
  • myelofibrosis
  • myeloproliferative neoplasms
  • ruxolitinib
  • splenomegaly

ASJC Scopus subject areas

  • Hematology

Cite this

Harrison, C., Mesa, R., Ross, D., Mead, A., Keohane, C., Gotlib, J., & Verstovsek, S. (2013). Practical management of patients with myelofibrosis receiving ruxolitinib. Expert Review of Hematology, 6(5), 511-523. https://doi.org/10.1586/17474086.2013.827413

Practical management of patients with myelofibrosis receiving ruxolitinib. / Harrison, Claire; Mesa, Ruben; Ross, David; Mead, Adam; Keohane, Clodagh; Gotlib, Jason; Verstovsek, Srdan.

In: Expert Review of Hematology, Vol. 6, No. 5, 2013, p. 511-523.

Research output: Contribution to journalArticle

Harrison, C, Mesa, R, Ross, D, Mead, A, Keohane, C, Gotlib, J & Verstovsek, S 2013, 'Practical management of patients with myelofibrosis receiving ruxolitinib', Expert Review of Hematology, vol. 6, no. 5, pp. 511-523. https://doi.org/10.1586/17474086.2013.827413
Harrison, Claire ; Mesa, Ruben ; Ross, David ; Mead, Adam ; Keohane, Clodagh ; Gotlib, Jason ; Verstovsek, Srdan. / Practical management of patients with myelofibrosis receiving ruxolitinib. In: Expert Review of Hematology. 2013 ; Vol. 6, No. 5. pp. 511-523.
@article{4ec899e703e74e65aba85f36b3f1bbd6,
title = "Practical management of patients with myelofibrosis receiving ruxolitinib",
abstract = "Myelofibrosis (MF) is characterized by bone marrow fibrosis, progressive anemia and extramedullary hematopoiesis, primarily manifested as splenomegaly. Patients also experience debilitating constitutional symptoms, including sequelae of splenomegaly, night sweats and fatigue. Ruxolitinib (INC424, INCB18424, Jakafi, Jakavi), a JAK1 and JAK2 inhibitor, was approved in November 2011 by the US FDA for the treatment of intermediate-or high-risk MF, and more recently in Europe and Canada for the treatment of MF-related splenomegaly or symptoms. These approvals were based on data from two randomized Phase III studies: COMFORT-I randomized against placebo, and COMFORT-II randomized against best available therapy. In these studies, ruxolitinib rapidly improved multiple disease manifestations of MF, reducing splenomegaly and improving quality of life of patients and potentially prolonging survival. However, as with other chemotherapies, ruxolitinib therapy is associated with some adverse events, such as anemia and thrombocytopenia. The aims of this article are to provide a brief overview of ruxolitinib therapy, to discuss some common adverse events associated with ruxolitinib therapy and to provide clinical management recommendations to maximize patients' benefit from ruxolitinib.",
keywords = "JAK inhibitor, myelofibrosis, myeloproliferative neoplasms, ruxolitinib, splenomegaly",
author = "Claire Harrison and Ruben Mesa and David Ross and Adam Mead and Clodagh Keohane and Jason Gotlib and Srdan Verstovsek",
year = "2013",
doi = "10.1586/17474086.2013.827413",
language = "English (US)",
volume = "6",
pages = "511--523",
journal = "Expert Review of Hematology",
issn = "1747-4086",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Practical management of patients with myelofibrosis receiving ruxolitinib

AU - Harrison, Claire

AU - Mesa, Ruben

AU - Ross, David

AU - Mead, Adam

AU - Keohane, Clodagh

AU - Gotlib, Jason

AU - Verstovsek, Srdan

PY - 2013

Y1 - 2013

N2 - Myelofibrosis (MF) is characterized by bone marrow fibrosis, progressive anemia and extramedullary hematopoiesis, primarily manifested as splenomegaly. Patients also experience debilitating constitutional symptoms, including sequelae of splenomegaly, night sweats and fatigue. Ruxolitinib (INC424, INCB18424, Jakafi, Jakavi), a JAK1 and JAK2 inhibitor, was approved in November 2011 by the US FDA for the treatment of intermediate-or high-risk MF, and more recently in Europe and Canada for the treatment of MF-related splenomegaly or symptoms. These approvals were based on data from two randomized Phase III studies: COMFORT-I randomized against placebo, and COMFORT-II randomized against best available therapy. In these studies, ruxolitinib rapidly improved multiple disease manifestations of MF, reducing splenomegaly and improving quality of life of patients and potentially prolonging survival. However, as with other chemotherapies, ruxolitinib therapy is associated with some adverse events, such as anemia and thrombocytopenia. The aims of this article are to provide a brief overview of ruxolitinib therapy, to discuss some common adverse events associated with ruxolitinib therapy and to provide clinical management recommendations to maximize patients' benefit from ruxolitinib.

AB - Myelofibrosis (MF) is characterized by bone marrow fibrosis, progressive anemia and extramedullary hematopoiesis, primarily manifested as splenomegaly. Patients also experience debilitating constitutional symptoms, including sequelae of splenomegaly, night sweats and fatigue. Ruxolitinib (INC424, INCB18424, Jakafi, Jakavi), a JAK1 and JAK2 inhibitor, was approved in November 2011 by the US FDA for the treatment of intermediate-or high-risk MF, and more recently in Europe and Canada for the treatment of MF-related splenomegaly or symptoms. These approvals were based on data from two randomized Phase III studies: COMFORT-I randomized against placebo, and COMFORT-II randomized against best available therapy. In these studies, ruxolitinib rapidly improved multiple disease manifestations of MF, reducing splenomegaly and improving quality of life of patients and potentially prolonging survival. However, as with other chemotherapies, ruxolitinib therapy is associated with some adverse events, such as anemia and thrombocytopenia. The aims of this article are to provide a brief overview of ruxolitinib therapy, to discuss some common adverse events associated with ruxolitinib therapy and to provide clinical management recommendations to maximize patients' benefit from ruxolitinib.

KW - JAK inhibitor

KW - myelofibrosis

KW - myeloproliferative neoplasms

KW - ruxolitinib

KW - splenomegaly

UR - http://www.scopus.com/inward/record.url?scp=84885906469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885906469&partnerID=8YFLogxK

U2 - 10.1586/17474086.2013.827413

DO - 10.1586/17474086.2013.827413

M3 - Article

C2 - 24083419

AN - SCOPUS:84885906469

VL - 6

SP - 511

EP - 523

JO - Expert Review of Hematology

JF - Expert Review of Hematology

SN - 1747-4086

IS - 5

ER -